ライフサイエンスコーパス: IPV

1 IPV victims underwent more imaging studies in the preced

2 IPV was administered by needle-syringe as an intramuscul

3 IPV was estimated during the first 15 days post-LT.

4 IPV-related firearm laws (predictor) and annual, state-s

5 IPV-vaccinated participants were randomly assigned to re

6 INTERPRETATION: The lowest dose (1/10 IPV-Al) of the vaccine performed well both after two and

7 5 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive IPV.

8 type 2), and 98.5% (n=202, type 3); and 1/10 IPV-Al: 98.5% (n=201, type 1), 94.6% (n=193, type 2), an

9 e [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10,

10 of 1670 IIV3 recipients and 81 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74.2% [57

11 f 1705 IIV3 recipients and 182 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41.0% [24

12 Seroconversion after 2 IPV doses in each arm were as follows: (A) 97.3% (90.6-9

13 o vaccine-naive Cuban infants who received 2 IPV doses at 4 and 8 months of age.

14 ded programme of immunisation schedule): 1/3 IPV-Al 98.5% (n=202, type 1), 97.6% (n=200; type 2), and

15 s; 205 were randomly assigned to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 I

16 formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times

17 We considered 4 IPV-related outcomes: reporting a controlling partner (a

18 ) of 4323 IIV3-allocated and 60 (1%) of 4121 IPV-allocated household unvaccinated individuals.

19 ed to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive I

20 200; type 2), and 99.5% (n=204, type 3); 1/5 IPV-Al: 99.5% (n=204, type 1), 96.1% (n=197, type 2), an

21 e [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) i

22 Knowledge about IPV was high among vaccinators (94%).

23 which limited countries' abilities to access IPV in a timely manner, 105 of 126 countries using OPV o

24 During 2013-2015, 85 countries added IPV to their immunization schedules, 46 (55%) of which a

25 IPV, by June all LGAs had HFs administering IPV and by July, 91% of the HFs in Kano reported adminis

26 f LGAs had at least 20% of HFs administering IPV, by June all LGAs had HFs administering IPV and by J

27 1% of the HFs in Kano reported administering IPV.

28 s remained elevated 6 and 11 months after an IPV boost, although at a lower level than reported at 1

29 ved intensive IPV education and delivered an IPV intervention that included a clinical pathway to gui

30 The addition of one or two full doses of an IPV after a bivalent OPV schedule increased the RR to 0.

31 However, the addition of an IPV to bivalent OPV schedules did not significantly incr

32 rth, 6 and 10 weeks, bOPV+IPV at week 14 and IPV at week 18.

33 onversion rate difference between IPV-Al and IPV was greater than -10%.

34 the association between mental disorders and IPV perpetrated by men towards women in a population-bas

35 th stronger associations between drought and IPV among adolescent girls and unemployed women.

36 ized mediating variables linking drought and IPV, prohibiting a formal mediation analysis.

37 The interaction of FKBP5 and IPV affects the physiological response to stress early i

38 ith two copies of a risk FKBP5 haplotype and IPV exposure were significantly more likely to have a de

39 here are biosafety concerns for both OPV and IPV.

40 rrhea was not different between the tOPV and IPV groups (P = .18), the number of days with diarrhea (

41 valent OPV2 in previously OPV-vaccinated and IPV-vaccinated adults.

42 ps: group A received IPV at age 14 weeks and IPV booster at age 22 weeks; group B received IPV at age

43 ultilevel logistic regression models for any IPV and each type of IPV separately (physical violence,

44 Mothers exposed to any IPV were less likely to initiate breastfeeding early (ad

45 y was to investigate the association between IPV in tacrolimus exposure and immune-mediated graft inj

46 f the seroconversion rate difference between IPV-Al and IPV was greater than -10%.

47 assess the immunogenicity of the new bOPV + IPV immunization schedule and gains in type 2 immunity w

48 received bOPV at birth, 6 and 10 weeks, bOPV+IPV at week 14 and IPV at week 18.

49 Both IPV and fIPV were administered on the outer, upper right

50 ered in the Western Pacific Region with both IPV introduction and the tOPV-bOPV switch were related t

51 home visitation program with a comprehensive IPV intervention, compared with the home visitation prog

52 sual wild-type strains used for conventional IPV (cIPV).

53 However, current IPV delivery is less suitable for campaign use than OPV,

54 fIPV, 0.2 mL im; (C) fIPV, 0.1mL id; and (D) IPV, 0.5 mL im.

55 been ongoing since 2014, including delaying IPV introduction in countries where risks of type 2 rein

56 ve (AUC) of the multivariate model to detect IPV (0.87 vs 0.86, P < .01), and the cross-validated mul

57 ulation is a crucial milestone in developing IPV-Al.

58 with 2 doses of intradermal fractional-dose IPV (fIPV) in its routine immunization schedule.

59 tered intradermally, compared with full-dose IPV administered intramuscularly, among adults with a hi

60 e similar in children who received full-dose IPV and those who received fIPV (1:64 vs 1:45, respectiv

61 ng immune responses, compared with full-dose IPV.

62 Type 2 seroconversion with one dose IPV in Arm A was 72.0% (95%CI:66.2-77.3), which increase

63 lio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously v

64 Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PC

65 Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well toler

66 ear physical and/or sexual IPV and emotional IPV, HIV/AIDs knowledge and behaviors, decision-making,

67 lts The majority of patients who experienced IPV (mean age, 34.2 years +/- 12.2 [standard deviation])

68 Patients who experienced IPV during the COVID-19 pandemic were more likely to be

69 2-dose fractional-IPV schedule could extend IPV immunization to more children.

70 ne production and an unforecasted demand for IPV use in campaigns to interrupt wild polio virus and t

71 ing a controlling partner (a risk factor for IPV) and experiencing emotional violence, physical viole

72 significant contributor to women's risk for IPV.

73 orm the argument for antenatal screening for IPV in LMICs and the provision of services to not only i

74 eral manufacturers use Sabin OPV strains for IPV production (sIPV), rather than the usual wild-type s

75 iance) approved the provision of support for IPV introduction in the 72 Gavi-eligible countries.

76 to provide exceptional financial support for IPV introduction to additional OPV-only using countries

77 y block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al],

78 izing wastage and use of a 2-dose fractional-IPV schedule could extend IPV immunization to more child

79 tients reporting physical abuse arising from IPV during the statewide COVID-19 pandemic between March

80 were connected and conveyed protection from IPV.

81 type 2 (PV2) in children who received 1 full IPV dose and between 78% and 100% in those receiving 2 f

82 d compared it with those who received 1 full IPV dose.

83 aring strategy to stretch the limited global IPV supply while further improving population immunity.

84 High IPV in tacrolimus exposure beyond month 6 postliver tran

85 een very early postoperative over IS or high IPV and long-term outcome measures following LT.

86 composite endpoint between the low- and high-IPV groups (P = 0.068).

87 A higher IPV in combination with a low kidney function at baselin

88 We determined factors impacting IPV introduction and the value of the RI module on monit

89 In IPV-vaccinated participants, solicited adverse events oc

90 enrolled (3918 in IIV3 villages and 3848 in IPV villages).

91 OPV2 candidates were safe and immunogenic in IPV-immunised adults, and our data support the further d

92 dence, patterns, and severity of injuries in IPV victims during the COVID-19 pandemic in 2020 compare

93 Mean reduction in IPV (via SVAWS subscale score) at 12 months post-baselin

94 ge have not consistently shown reductions in IPV.

95 ve-attenuated oral (OPV) and/or inactivated (IPV) PV vaccines have systematically reduced its spread

96 Challenges among HFs included: IPV shortages (20%), hesitancy to administer 2 injectabl

97 use device to administer vaccines, including IPV.

98 ted poliovirus vaccine (fIPV) could increase IPV affordability and stretch limited supplies.

99 In addition, increased IPV risk was also found in those without previous IPV ag

100 s the Nanopatch could facilitate inexpensive IPV vaccination in campaign settings.

101 e these efforts, there is still insufficient IPV supply to meet demand.

102 s across 7 sites), nurses received intensive IPV education and delivered an IPV intervention that inc

103 n 2014 and 2016, 11 EMR countries introduced IPV in their routine immunization program, including all

104 ot use IPV by the end of 2014 had introduced IPV.

105 A total of 105 countries have introduced IPV as of September 2016 of which 85 have procured the v

106 5 of 126 countries using OPV only introduced IPV within a 2.5-year period, making it the fastest roll

107 Bangladesh successfully introduced IPV, but shortages related to insufficient global supply

108 tations, we found that BAG3 uses both of its IPV motifs to interact with sHsps, including Hsp27 (HspB

109 0.812 and P = 0.451) nor in high versus low IPV (P = 0.835).

110 terial etiology (P = .0099) compared to male IPV recipients but equally likely to experience diarrhea

111 liovirus vaccine ([fIPV] one fifth of normal IPV dose) is safe and immunogenic; however, id administr

112 572 IIV3 recipients and 206 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25.6% [95% C

113 d capacity building, to ensure acceptance of IPV and continued uptake of OPV.

114 In many countries, the addition of IPV would necessitate delivery of multiple injectable va

115 e on multi-dose vial policy (30%) and age of IPV administration (8%).

116 ssment approaches were used: (1) analysis of IPV vaccinations reported in NHMIS, and (2) survey of 20

117 e required to measure the antigen content of IPV products consistently.

118 The findings support the development of IPV risk identification and prevention services among me

119 cantly higher (p<0.0001) than to one dose of IPV (groups A and B) for all three poliovirus serotypes:

120 0 weeks, and 14 weeks and either one dose of IPV at age 14 weeks or two doses of IPV at age 14 weeks

121 rats that received 1/40th of a human dose of IPV delivered by Nanopatch, but not in rats given 1/8th

122 t in intestinal immunity following a dose of IPV given to OPV-immunized children.

123 e rapid introduction of at least one dose of IPV into routine immunization schedules in 126 all OPV-u

124 infants) were allocated bOPV and one dose of IPV, and 22 villages (329 infants) were assigned bOPV an

125 e 2 immunity with addition of second dose of IPV.

126 immunised with bOPV and one or two doses of IPV and those who received tOPV (15 of 252 [6%] vs six o

127 dose of IPV at age 14 weeks or two doses of IPV at age 14 weeks and 18 weeks.

128 nificantly with bOPV and one or two doses of IPV compared with tOPV (17 of 751 [2%] vs three of 353 [

129 inst poliovirus type 2 after 1 to 2 doses of IPV respectively.

130 eceiving bOPV and either one or two doses of IPV, but transmission was not increased in the community

131 infants) were assigned bOPV and two doses of IPV.

132 (CETA) in reducing (a) women's experience of IPV and (b) their male partner's alcohol misuse among co

133 ndicates that mothers exposed to any form of IPV (physical, sexual, or emotional violence) were less

134 sults may be limited to more severe forms of IPV perpetration.

135 ing monovalent and trivalent formulations of IPV.

136 Effective implementation of IPV introduction and the switch from trivalent OPV (cont

137 the lessons learned from the introduction of IPV and the switch from tOPV to bOPV can be useful for t

138 role played by NITAGs in the introduction of IPV in the routine immunization program and the lessons

139 sing IPV except Egypt, where introduction of IPV was delayed by a global shortage.

140 The introduction of IPV was largely successful in Kano and the RI module was

141 egulatory issues before the introductions of IPV and bOPV.

142 en who reported moderate or higher levels of IPV and their male partners with hazardous alcohol use w

143 ght was protective for at least 1 measure of IPV: Namibia, Tanzania, and Uganda.

144 that drought was associated with measures of IPV towards women, with larger positive associations amo

145 Men reported more lifetime perpetration of IPV (physical or sexual IPV range 32.5%-80%) than women

146 ly reduced experience of and perpetration of IPV when delivered to men and led to more equitable hous

147 s as an approach to reduce the prevalence of IPV.

148 his article is to systematize the process of IPV introduction and switch in Latin America and the Car

149 ntions of arm B with additional provision of IPV delivered at the maternal and child health camps (ar

150 The absolute rates of IPV against women ranged from 0.1% to 2.1% across diagno

151 control group of 555 subjects (1:3 ratio of IPV victims to control subjects) who presented to the ED

152 We also estimated the hazard ratios of IPV against women in unaffected full siblings (ranging f

153 ntrols), and calculated the hazard ratios of IPV against women.

154 Sensitivity analyses showed higher risk of IPV against women in men when comorbid substance use dis

155 sm were associated with an increased risk of IPV against women in men, with hazard ratios ranging fro

156 d personality disorders had a higher risk of IPV against women than their unaffected siblings, with R

157 nd acceptance of the recommended schedule of IPV by the SAGE, but the evidence was largely from devel

158 en delayed because of the global shortage of IPV, making it unavailable to select lower-risk countrie

159 e associations were similar for each type of IPV and were overall consistent across infant's sex and

160 gression models for any IPV and each type of IPV separately (physical violence, sexual violence, and

161 sting for all 3 types of IPV, all 3 types of IPV were independently associated with decreased likelih

162 simultaneously adjusting for all 3 types of IPV, all 3 types of IPV were independently associated wi

163 th, and the possibility of underreporting of IPV experiences attenuating the magnitude of observed as

164 sional societies, thus encouraging uptake of IPV as a second or third injection in an accelerated man

165 These results suggest that victims of IPV delayed reaching out to health care services until t

166 000 and January 2019) with data available on IPV and breastfeeding practices were used.

167 were offered a short educational session on IPV.

168 The impact of the supply situation on IPV introduction timelines in countries are the focus of

169 In many ways, the IMG's work on IPV introduction can serve as a model for other vaccine

170 o eradication programme, the addition of one IPV dose for all birth cohorts should be prioritised to

171 immunogenicity of two fIPV doses versus one IPV dose for routine immunisation, and also assessed the

172 ther research should explore how to optimize IPV prevention interventions to target related risks of

173 measures for the study were coverage of OPV, IPV, and routine extended programme on immunisation vacc

174 l], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks

175 fIPV or IPV were administered on days 0 and 28; serum was collec

176 assigned to receive mIPV2HD (117 infants) or IPV (116 infants).

177 ype 2 vaccine derived polio virus outbreaks, IPV supplies are severely constrained.

178 The primary outcome, IPV, was assessed by the Severity of Violence Against Wo

179 evalence rates of past-year male-perpetrated IPV and nonpartner rape from women's and men's reports a

180 linked to an increased risk of perpetrating IPV against women, the direction and magnitude of the as

181 iated with an increased risk of perpetrating IPV towards women, and that substance use disorders, as

182 , 95% CI: 1.32-2.62, p < 0.001) and physical IPV (DD = -7.9 pp, ROR: 0.60, 95% CI: 0.36-0.99, p = 0.0

183 ted and compared with 42 victims of physical IPV (mean age, 41 years +/- 15; 40 women) from 2017 to 2

184 ature regarding the exacerbation of physical IPV during the coronavirus disease 2019 (COVID-19) pande

185 Results A total of 26 victims of physical IPV from 2020 (mean age, 37 years +/- 13 [standard devia

186 ring the pandemic, the incidence of physical IPV was 1.8 times greater (95% CI: 1.1, 3.0; P = .01).

187 perience of past-year sexual and/or physical IPV: (1) poverty, (2) all childhood trauma, (3) quarrell

188 n reduced perpetration of past-year physical IPV.

189 es, we examined the contribution of previous IPV against women and common psychiatric comorbidities,

190 isk was also found in those without previous IPV against women.

191 1-4 years were randomized (1:1:1) to receive IPV at 5 months (arm A), at enrollment (arm B), or no va

192 4 to receive 1/10 IPV-Al, and 206 to receive IPV.

193 vaccine, respectively, but only 65% received IPV at the same visit.

194 eeks to one of four groups: group A received IPV at age 14 weeks and IPV booster at age 22 weeks; gro

195 PV booster at age 22 weeks; group B received IPV at age 14 weeks and fIPV booster at age 22 weeks; gr

196 Arm B received IPV each at 6, 10, 14 weeks and bOPV at 18 weeks of age.

197 PV booster at age 22 weeks; group C received IPV at age 6 weeks and fIPV booster at age 22 weeks; and

198 uring a single visit, with infants receiving IPV alongside pentavalent vaccine (which covers diphther

199 erpetration of sexual IPV but did not reduce IPV when delivered to couples or women.

200 was more effective than TAU-Plus in reducing IPV and hazardous alcohol use among high-risk couples in

201 the overall number of patients who reported IPV decreased during the pandemic, the incidence of phys

202 As a result, IPV was introduced in mass campaigns to help achieve pol

203 ias, and low statistical power for secondary IPV outcomes.

204 We found evidence of decreased sexual IPV with men's UBL across men's and women's reports and

205 educing self-reported perpetration of sexual IPV but did not reduce IPV when delivered to couples or

206 men's perpetration of physical and/or sexual IPV (AOR = 0.78; 95% CI: 0.62-0.98, p = 0.037).

207 perience of past-year physical and/or sexual IPV (AOR = 0.81, 95% CI: 0.66-0.99, p = 0.036) and men's

208 .02, 95% CI: 0.81-1.28, p = 0.865) or sexual IPV (couples' UBL arm AOR = 0.86, 95% CI: 0.62-1.20, p =

209 s experience of past-year physical or sexual IPV 24 months postintervention.

210 etration of past-year physical and/or sexual IPV and emotional IPV, HIV/AIDs knowledge and behaviors,

211 ciated with past-year physical and/or sexual IPV exposure; of particular interest is the resilience p

212 s experience of past-year physical or sexual IPV from women's reports and factors driving women's pas

213 rly different from men's (physical or sexual IPV range 10.1%-34.0%).

214 han women did experience (physical or sexual IPV range 27.5%-67.4%), but women's reports of past-year

215 time perpetration of IPV (physical or sexual IPV range 32.5%-80%) than women did experience (physical

216 of past-year experience (physical or sexual IPV range 8.2%-32.1%) were not very clearly different fr

217 perpetration of past-year physical or sexual IPV, comprehensive HIV knowledge, and condom use at last

218 educed male perpetration of past-year sexual IPV (AOR: 0.73; 95% CI: 0.56-0.94, p = 0.014), and no in

219 control arm households were offered a short IPV educational session.

220 Specifically, IPV was released in two separate bursts, mimicking the d

221 riority of three IPV-Al vaccines to standard IPV.

222 rmation for abused women but no standardized IPV training for nurses.

223 To study the association between state IPV-related firearm laws and IPH rates over a 25-year pe

224 understanding of the methodology behind Tac IPV is imperative to its recognition as an important pro

225 ed to be the primary determinant of high Tac IPV and perhaps the most modifiable risk factor.

226 Higher Tac IPV has been associated with a number of mechanisms lead

227 interventions targeting MNA and reducing Tac IPV are crucial to improving long-term graft survival.

228 focused on Tac intrapatient variability (Tac IPV) as a novel marker to better assess patient risk.

229 ansplanted between 2000 and 2015, tacrolimus IPV was calculated from at least 5 tacrolimus trough sam

230 omes were the association between tacrolimus IPV on (1) loss of renal function per year of follow-up

231 ical work and stakeholder consultations, the IPV Immunization Systems Management Group (IMG) presente

232 98.0% (P = 1.00), and 99.2% (P = .45) in the IPV arm.

233 = .05, respectively) more frequently in the IPV group than in the control group.

234 and 235 [13%] of 1796, respectively, in the IPV group).

235 as administered intradermally (0.1 mL of the IPV formulation was administered using the 0.1 mL HelmJe

236 ical records of 185 patients referred to the IPV support program from the emergency department (ED) b

237 ticle, and based on lessons learned with the IPV introductions, it is recommended for future health p

238 ial was to show the non-inferiority of three IPV-Al vaccines to standard IPV.

239 s 1, 2, and 3 was already high for the three IPV-Al vaccines after two vaccinations, but was higher a

240 Alliance, UNICEF set out to secure access to IPV supply for around 100 countries.

241 ld include tertiary prevention approaches to IPV, such as CETA, rather than offering only community m

242 to IIV3 and 949 households were assigned to IPV.

243 including one death; none were attributed to IPV or fIPV.

244 d the prevalence of any lifetime exposure to IPV among mothers was 33.3% (27.6% for physical violence

245 ilable and who were assessed for exposure to IPV during the first 2 years of life as well as multiple

246 ined the association of maternal exposure to IPV with early initiation of breastfeeding (within 1 hou

247 weeks, the fIPV booster was non-inferior to IPV (group B vs group A) for serotype 1 (-1.12% [90% CI

248 Our analyses were restricted to IPV leading to arrest, suggesting that the applicability

249 State laws that prohibit persons subject to IPV-related restraining orders from possessing firearms

250 5 of 17 countries and areas that did not use IPV by the end of 2014 had introduced IPV.

251 the end of 2016 all EMR countries were using IPV except Egypt, where introduction of IPV was delayed

252 tOPV (n = 315) or inactivated polio vaccine (IPV) (n = 299) at 39 weeks.

253 troduction of the inactivated polio vaccine (IPV) and the switch from trivalent oral polio vaccine (t

254 a have introduced inactivated polio vaccine (IPV) as part of the Global Polio Eradication and Endgame

255 e introduction of inactivated polio vaccine (IPV) in combination with OPV.

256 orts to introduce inactivated polio vaccine (IPV) into all countries that did not yet include it in t

257 lbania introduced inactivated polio vaccine (IPV) into its immunization system in May 2014, increasin

258 geria, introduced inactivated polio vaccine (IPV) into its routine immunization (RI) schedule in Marc

259 t least 1 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2

260 t least 1 dose of inactivated polio vaccine (IPV) into the routine immunization programs of all count

261 t least 1 dose of inactivated polio vaccine (IPV) into their routine immunization schedules by the en

262 ) and one dose of inactivated polio vaccine (IPV) where available.

263 sets, introducing inactivated polio vaccine (IPV), and replacing trivalent oral polio vaccine with bi

264 immunization with inactivated polio vaccine (IPV), to ensure type 2 immunity.

265 sphere IIV3 or an inactivated polio vaccine (IPV).

266 ges in the use of inactivated polio vaccine (IPV).

267 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), startin

268 s' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunizatio

269 showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in children previously i

270 a control of inactivated poliovirus vaccine (IPV) in the beginning of the study; vaccination occurred

271 ither OPV or inactivated poliovirus vaccine (IPV) in the novel OPV2 phase 2 study, with no dose withi

272 ular dose of inactivated poliovirus vaccine (IPV) with 2 doses of intradermal fractional-dose IPV (fI

273 V), and injected inactivated polio vaccines (IPV) has almost achieved global eradication of wild poli

274 placed with inactivated poliovirus vaccines (IPV).

275 cement with inactivated poliovirus vaccines (IPVs).

276 hibitor levels and intrapatient variability (IPV) in a multicenter, retrospective cohort.

277 A high intrapatient variability (IPV) in tacrolimus exposure is associated with impaired

278 Intimate partner violence (IPV) against women is a major global health issue, parti

279 Intimate partner violence (IPV) against women is associated with a wide range of ad

280 Both intimate partner violence (IPV) and alcohol misuse are highly prevalent, and partne

281 male-perpetrated intimate partner violence (IPV) and risk factors is essential for building evidence

282 erity of physical intimate partner violence (IPV) during the coronavirus disease 2019 (COVID-19) pand

283 Background Intimate partner violence (IPV) is a global social and public health problem, but p

284 Intimate partner violence (IPV) is a public health problem with significant adverse

285 Intimate partner violence (IPV) is associated with increased HIV risk and other adv

286 Intimate partner violence (IPV) is linked to substance use by male perpetrators and

287 arm possession by intimate partner violence (IPV) offenders.

288 ch as exposure to intimate partner violence (IPV), to predict self-regulation indicators and associat

289 s associated with intimate partner violence (IPV).

290 tween drought and intimate partner violence (IPV).

291 dge, and physical intimate partner violence (IPV).

292 4345 children (2132 with IIV3 and 2213 with IPV) from 1868 households (968 with IIV3 and 900 with IP

293 1868 households (968 with IIV3 and 900 with IPV) with 10 813 unvaccinated household contacts.

294 ical variables independently associated with IPV were race (odds ratio [OR] range, 3.2-5.9; 95% confi

295 on images were independently associated with IPV.

296 No problems with IPV storage, transport, or waste disposal were detected,

297 Among 73 infants not vaccinated with IPV, 58% of caregivers reported that vaccine was unavail

298 alth who had previously been vaccinated with IPV, and who would not have any contact with immunosuppr

299 50 participants, previously vaccinated with IPV, were assigned to novel OPV2-c1 (n=17), novel OPV2-c

300 Past-year IPV indicators based on women's reported experience that